Cara Therapeutics, INC 8-K filings

Tvardi Therapeutics reported second quarter 2026 results, highlighting positive healthy volunteer data for its next-generation STAT3 inhibitor TTI-109 and selecting ulcerative colitis as its initial indication, while also noting a reduced cash position.

Tvardi Therapeutics has chosen ulcerative colitis as the initial indication for its STAT3 inhibitor, TTI-109, following promising Phase 1 study results.

Tvardi Therapeutics announced an increase to its at-the-market offering program, allowing for the issuance of up to an additional $9.69 million in common stock.

Tvardi Therapeutics announced positive Phase 1 results for its next-generation STAT3 inhibitor, TTI-109, demonstrating improved tolerability and pharmacodynamic evidence of STAT3 target engagement.

Tvardi Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders held on June 9, 2026, including the election of directors and ratification of its independent auditor.

Tvardi Therapeutics reported Q1 2026 financial results, highlighting progress in its STAT3 inhibitor programs TTI-109 and TTI-101, with key clinical data expected in June and 2H 2026.

Tvardi Therapeutics announced its fourth quarter and full-year 2025 financial results, showing reduced net losses, but also a delay in topline data for its TTI-101 hepatocellular carcinoma trial to the second half of 2026.

Tvardi Therapeutics, Inc. announced the date for its 2026 Annual Meeting of Stockholders and associated deadlines for stockholder proposals and director nominations.

Tvardi Therapeutics provided an updated corporate presentation detailing progress on its STAT3 inhibitor programs, TTI-101 and TTI-109, across idiopathic pulmonary fibrosis and hepatocellular carcinoma, with key data readouts anticipated in the first half of 2026.

Tvardi Therapeutics, Inc. approved new retention compensation and a comprehensive severance and change in control plan for its executive officers and certain employees.

Tvardi Therapeutics, Inc. provided a corporate presentation detailing encouraging interim Phase 1b/2 data for TTI-101 in hepatocellular carcinoma and progress on its next-generation STAT3 inhibitor, TTI-109.

Tvardi Therapeutics announced mixed third-quarter 2025 results, with a key IPF trial failing to meet its goals, but progress in oncology programs and an extended cash runway into Q4 2026.

Tvardi Therapeutics announced that its Phase 2 REVERT trial for TTI-101 in idiopathic pulmonary fibrosis did not meet its primary goals.

Tvardi Therapeutics announced its second quarter 2025 financial results, highlighting progress in its clinical trials for fibrosis-driven diseases and an extended cash runway into Q4 2026.

Dr. Shaheen Wirk has resigned from the Board of Directors of Tvardi Therapeutics, Inc., effective July 8, 2025, with the company stating no disagreement was involved.

Tvardi Therapeutics, Inc. has updated its corporate presentation, showcasing encouraging preliminary clinical data for its lead drug candidate TTI-101 in Idiopathic Pulmonary Fibrosis and Hepatocellular Carcinoma, alongside the Investigational New Drug (IND) filing for its next-generation STAT3 inhibitor, TTI-109.

Tvardi Therapeutics, Inc. announced the successful completion of enrollment for its Phase 2 clinical trial of TTI-101 in patients with idiopathic pulmonary fibrosis, with key topline data anticipated in the fourth quarter of 2025.

Tvardi Therapeutics reports its first quarter 2025 results, highlighting the completion of its merger with Cara Therapeutics and providing a business update on its clinical programs.

Tvardi Therapeutics amends its 8-K filing to include financial results for the quarter ended March 31, 2025, following its merger with Cara Therapeutics, highlighting its focus on developing STAT3 inhibitors for fibrosis-driven diseases.

Tvardi Therapeutics finalizes its merger with Cara Therapeutics, becoming a Nasdaq-listed entity focused on STAT3-targeting therapies for fibrosis-driven diseases.

Cara Therapeutics is set to merge with Tvardi Therapeutics, a biopharmaceutical company specializing in STAT3-targeting therapies for fibrosis-driven diseases, with the combined entity focusing on advancing Tvardi's programs.

Cara Therapeutics stockholders greenlit the merger with Tvardi Therapeutics, paving the way for a reverse recapitalization.

Cara Therapeutics provides supplemental disclosures to its proxy statement/prospectus regarding the merger with Tvardi Therapeutics in response to stockholder demands and lawsuits alleging materially false and misleading statements.

Cara Therapeutics and Tvardi Therapeutics have agreed to merge, creating a combined entity focused on developing novel therapies targeting STAT3 for fibrosis-driven diseases.

Cara Therapeutics has regained compliance with Nasdaq's minimum bid price requirement but still needs to address a stockholders' equity deficiency.

Cara Therapeutics has completed a 1-for-12 reverse stock split and reduced its authorized shares, effective December 30, 2024.

Cara Therapeutics and Tvardi Therapeutics have agreed to merge, creating a combined entity focused on developing Tvardi's STAT3-targeting therapies for fibrosis-driven diseases.

Cara Therapeutics and Tvardi Therapeutics have agreed to merge, forming a Nasdaq-listed company focused on developing novel treatments for fibrosis-driven diseases by targeting STAT3.

Cara Therapeutics has received a delisting notice from Nasdaq due to insufficient stockholders' equity and is also working to regain compliance with minimum bid price requirements.

Cara Therapeutics has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement, resulting in a transfer of its stock listing to the Nasdaq Capital Market.